Drupal.behaviors.print = function(context) {window.print();window.close();}>
Sequenom Boosts Prenatal IP Portfolio with Helicos Patents; Raises MaterniT21 Sales Projections
April 18, 2012
Sequenom Boosts Prenatal IP Portfolio with Helicos Patents; Raises MaterniT21 Sales Projections
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Cost Effectiveness Study Shows Sequencing-Based T21 Test Leads to Better Clinical Outcomes
May 2, 2012 / Clinical Sequencing News
As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
March 14, 2012 / Clinical Sequencing News
New Products: Sequenom's MaterniT21 Plus
February 8, 2012 / Clinical Sequencing News
Sequenom Runs More Than 13K T21 Tests in Q2; Plans to Expand Capacity in US and Overseas
August 1, 2012 / Clinical Sequencing News
As Rivals Vie for Share of Noninvasive Trisomy Testing Market, Physicians See Value for Screening
July 3, 2012 / Clinical Sequencing News